The market expects Crown Holdings (CCK) to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended June 2025. This widely-known consensus outlook is important in assessing the company's earnings picture, but a powerful factor that might influence its near-term stock price is how the actual results compare to these estimates.The stock might move higher if these key numbers top expectations in the upcoming earnings report, which is expected to be released ...

Wall Street expects a year-over-year increase in earnings on higher revenues when HBT Financial (HBT) reports results for the quarter ended June 2025. While this widely-known consensus outlook is important in gauging the company's earnings picture, a powerful factor that could impact its near-term stock price is how the actual results compare to these estimates.The earnings report, which is expected to be released on July 21, might help the stock move higher if these key numbers are better than expectations ...

The market expects RLI Corp. (RLI) to deliver a year-over-year decline in earnings on higher revenues when it reports results for the quarter ended June 2025. This widely-known consensus outlook is important in assessing the company's earnings picture, but a powerful factor that might influence its near-term stock price is how the actual results compare to these estimates.The earnings report, which is expected to be released on July 21, might help the stock move higher if these key numbers are better than e ...

Wall Street expects a year-over-year decline in earnings on higher revenues when W.R. Berkley (WRB) reports results for the quarter ended June 2025. While this widely-known consensus outlook is important in gauging the company's earnings picture, a powerful factor that could impact its near-term stock price is how the actual results compare to these estimates.The stock might move higher if these key numbers top expectations in the upcoming earnings report, which is expected to be released on July 21. On the ...

Wall Street expects a year-over-year decline in earnings on higher revenues when Domino's Pizza (DPZ) reports results for the quarter ended June 2025. While this widely-known consensus outlook is important in gauging the company's earnings picture, a powerful factor that could impact its near-term stock price is how the actual results compare to these estimates.The earnings report, which is expected to be released on July 21, might help the stock move higher if these key numbers are better than expectations ...

The market expects Medpace (MEDP) to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended June 2025. This widely-known consensus outlook is important in assessing the company's earnings picture, but a powerful factor that might influence its near-term stock price is how the actual results compare to these estimates.The stock might move higher if these key numbers top expectations in the upcoming earnings report, which is expected to be released on Ju ...

The market expects Washington Trust Bancorp (WASH) to deliver flat earnings compared to the year-ago quarter on higher revenues when it reports results for the quarter ended June 2025. This widely-known consensus outlook is important in assessing the company's earnings picture, but a powerful factor that might influence its near-term stock price is how the actual results compare to these estimates.The earnings report, which is expected to be released on July 21, might help the stock move higher if these key ...

BOK Financial (BOKF) is expected to deliver a year-over-year decline in earnings on higher revenues when it reports results for the quarter ended June 2025. This widely-known consensus outlook gives a good sense of the company's earnings picture, but how the actual results compare to these estimates is a powerful factor that could impact its near-term stock price.The earnings report, which is expected to be released on July 21, might help the stock move higher if these key numbers are better than expectatio ...

Core Insights - The Travelers Companies, Inc. (TRV) is anticipated to show improvements in both revenue and earnings for the second quarter of 2025, with revenue expected to reach $12.20 billion, reflecting a 7.5% growth year-over-year [1] - The earnings consensus estimate is $3.49 per share, indicating a 39% increase from the previous year, despite a slight downward revision of 0.8% in the last 30 days [2][3] Revenue and Earnings Estimates - The Zacks Consensus Estimate for TRV's second-quarter revenues is $12.20 billion, which is a 7.5% increase from the prior year [1] - The earnings estimate is $3.49 per share, with a year-over-year increase of 39% [2] Earnings Prediction Model - The earnings prediction model indicates a potential earnings beat for Travelers, supported by a positive Earnings ESP of +8.76% and a Zacks Rank of 3 (Hold) [2][3] Segment Performance - All three segments are expected to perform well, with premiums projected to increase by 7.2% to $10.9 billion, driven by better pricing and strong retention [4] - The Personal Insurance segment is estimated to generate $4.4 billion in premiums, reflecting an 8.3% improvement year-over-year [6] - The Bond & Specialty Insurance segment is expected to reach $1 billion in premiums, indicating a 12.1% increase from the previous year [7] - The Business Insurance segment is projected to generate $5.4 billion in premiums, a 5.4% increase year-over-year [9] Investment Income - Net investment income is estimated to be approximately $725 million for the second quarter, with a Zacks Consensus Estimate of $945 million, representing a 6.8% increase from the prior year [5][8] Underwriting Profitability - Improved pricing and prudent underwriting practices are expected to enhance underwriting profitability, with the combined ratio estimated at 105.5 [10] Expense Outlook - Total expenses are anticipated to rise by 6.4% to $11.4 billion, influenced by higher claims and administrative costs [11]

Core Viewpoint - Johnson & Johnson (JNJ) is set to report its second-quarter 2025 results on July 16, with sales and earnings estimates of $22.79 billion and $2.66 per share respectively. The earnings estimates for 2025 and 2026 have seen slight increases over the past month [1][2]. Group 1: Earnings Performance - JNJ has consistently exceeded earnings expectations in the last four quarters, with an average earnings surprise of 5.71%. The most recent quarter showed a surprise of 7.78% [3][4]. - The company has an Earnings ESP of +2.40% and a Zacks Rank 2 (Buy), indicating a strong likelihood of a positive earnings surprise [4]. Group 2: Sales Drivers and Challenges - Sales in JNJ's Innovative Medicines segment are expected to be driven by key products like Darzalex, Tremfya, and Erleada, with projected sales of $3.45 billion, $1.08 billion, and $903.9 million respectively [6][7]. - The sales of Stelara are anticipated to decline due to biosimilar competition, with estimates pegged at $1.88 billion [8][9]. - The MedTech segment faces challenges in China due to a volume-based procurement program, but growth is expected from newly acquired businesses like Abiomed and Shockwave [12][13]. Group 3: Strategic Developments - JNJ's acquisition of Intra-Cellular Therapies for approximately $14.6 billion enhances its presence in the neurological and psychiatric drug market [24]. - The company is navigating significant headwinds, including the impact of the Stelara patent cliff and ongoing legal battles related to talc lawsuits [25][24]. Group 4: Stock Performance and Valuation - JNJ's stock has risen 10.3% this year, outperforming the industry and the S&P 500, with a current price/earnings ratio of 14.42, slightly below the industry average [16][19]. - The company is viewed as reasonably valued, with expectations for operational sales growth to accelerate in the second half of 2025 and beyond [27][19].